CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  Hernangómez, Miriam ^a   Klusáková, Ilona ^a   Joukal, Marek ^a   Hradilová Svíženská, Ivana ^a   Guaza, Carmen ^b   Dubovỳ, Petr ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTO CAJAL   (Spain)

Author keywords

Activated glial cells; Cytokines; Modulation; Neuroinflammation; Rat neuropathic pain model; Sterile nerve constriction

Indexed keywords

CD200 RECEPTOR; CD200FC; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIGENS, CD200; CD200R1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL ACTIVATION; CEREBROSPINAL FLUID; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL SCIATIC NERVE INJURY; GLIA CELL; HIND PAW; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LUMBAR SPINAL CORD; MALE; MECHANICAL HYPERSENSITIVITY; MICROGLIA; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERMAL HYPERSENSITIVITY; WESTERN BLOTTING; WITHDRAWAL REFLEX; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIA; HYPERALGESIA; INFLAMMATION; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; PHYSICAL STIMULATION; SCIATICA; SPINAL CORD; TIME FACTOR; WISTAR RAT;

ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPERALGESIA; INFLAMMATION; INJECTIONS, SPINAL; MALE; NEUROGLIA; PAIN THRESHOLD; PHYSICAL STIMULATION; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE; SCIATICA; SPINAL CORD; TIME FACTORS;

EID: 84960881537     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0508-8     Document Type: Article

References (74)

1. Berger JV, Knaepen L, Janssen SPM, Jaken RJP, Marcus MAE, Joosten EAJ, et al. Cellular and molecular insights into neuropathy-induced pain hypersensitivity for mechanism-based treatment approaches. Brain Res Rev. 2011;67(1-2):282-310.
2. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006; 52(1):77-92.
3. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nature Rev Neurosci. 2005;6(7):521-32.
4. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun. 2007;21(2):131-46.
5. Swett JE, Torigoe Y, Elie VR, Bourassa CM, Miller PG. Sensory neurons of the rat sciatic-nerve. Exp Neurol. 1991;114(1):82-103.
6. Klusakova I, Dubovy P. Experimental models of peripheral neuropathic pain based on traumatic nerve injuries-an anatomical perspective. Ann Anat. 2009;191(3):248-59.
7. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 2006;51(2):240-64.
8. Choi H-S, Roh D-H, Yoon S-Y, Moon J-Y, Choi S-R, Kwon S-G, et al. Microglial interleukin-1 beta in the ipsilateral dorsal horn inhibits the development of mirror-image contralateral mechanical allodynia through astrocyte activation in a rat model of inflammatory pain. Pain. 2015;156(6): 1046-59.
9. Gao YJ, Ji RR. Targeting astrocyte signaling for chronic pain. Neurotherapeutics. 2010;7(4):482-93.
10. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003;23(3):1026-40.
11. Yamamoto Y, Terayama R, Kishimoto N, Maruhama K, Mizutani M, Iida S, et al. Activated microglia contribute to convergent nociceptive inputs to spinal dorsal horn neurons and the development of neuropathic pain. Neurochem Res. 2015;40(5):1000-12.
12. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126(1):56-68.
13. Brazda V, Klusakova I, Svizenska IH, Dubovy P. Dynamic response to peripheral nerve injury detected by in situ hybridization of IL-6 and its receptor mRNAs in the dorsal root ganglia is not strictly correlated with signs of neuropathic pain. Mol Pain. 2013;9:42.
14. Dubovy P, Brazda V, Klusakova I, Hradilova-Svizenska I. Bilateral elevation of interleukin-6 protein and mRNA in both lumbar and cervical dorsal root ganglia following unilateral chronic compression injury of the sciatic nerve. J Neuroinflamm. 2013;10:55.
15. Hatashita S, Sekiguchi M, Kobayashi H, Konno SI, Kikuchi SI. Contralateral neuropathic pain and neuropathology in dorsal root ganglion and spinal cord following hemilateral nerve injury in rats. Spine. 2008;33(12):1344-51.
16. Dubovy P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and neuropathic pain induction. Ann Anat. 2011;194(4):267-75.
17. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171(6):3034-46.
18. Hatherley D, Lea SM, Johnson S, Barclay AN. Structures of CD200/CD200 receptor family and implications for topology, regulation, and evolution. Structure. 2013;21(5):820-32.
19. Koning N, Bo L, Hoek RM, Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol. 2007;62(5):504-14.
20. Dentesano G, Straccia M, Ejarque-Ortiz A, Tusell JM, Serratosa J, Saura J, et al. Inhibition of CD200R1 expression by C/EBP beta in reactive microglial cells. J Neuroinflamm. 2012;9:165.
21. Dentesano G, Serratosa J, Tusell JM, Ramon P, Valente T, Saura J, et al. CD200R1 and CD200 expression are regulated by PPAR-gamma in activated glial cells. Glia. 2014;62(6):982-98.
22. Gao S, Hao B, Yang XF, Chen WQ. Decreased CD200R expression on monocyte-derived macrophages correlates with Th17/Treg imbalance and disease activity in rheumatoid arthritis patients. Inflamm Res. 2014;63(6):441-50.
23. Koning N, Swaab DF, Hoek RM, Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol. 2009;68(2):159-67.
24. Costello DA, Lyons A, Denieffe S, Browne TC, Cox FF, Lynch MA. Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice. A role for toll-like receptor activation. J Biol Chem. 2011;286(40):34722-32.
25. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol. 2009;215(1):5-19.
26. Wang XJ, Ye M, Zhang YH, Chen SD. CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. J Neuroimmun Pharmacol. 2007;2(3):259-64.
27. Chitnis T, Imitola J, Wang Y, Elyaman W, Chawla P, Sharuk M, et al. Elevated neuronal expression of CD200 protects Wld(s) mice from inflammationmediated neurodegeneration. Am J Pathol. 2007;170(5):1695-712.
28. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000;290(5497):1768-71.
29. Meuth SG, Simon OJ, Gnimm A, Melzer N, Herrmann AM, Spitzer P, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol. 2008;194(1-2):62-9.
30. Lyons A, McQuillan K, Deighan BF, O'Reilly J-A, Downer EJ, Murphy AC, et al. Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Beh Immun. 2009;23(7):1020-7.
31. Koning N, van Eijk M, Pouwels W, Brouwer MSM, Voehringer D, Huitinga I, et al. Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation. J Innate Immun. 2010;2(2):195-200.
32. Cox FF, Carney D, Miller AM, Lynch MA. CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Beh Immun. 2012;26(5):789-96.
33. Hernangomez M, Mestre L, Correa FG, Loria F, Mecha M, Inigo PM, et al. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia. 2012; 60(9):1437-50.
34. Liu YR, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, et al. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci. 2010;30(6):2025-38.
35. Simelyte E, Criado G, Essex D, Uger RA, Feldmann M, Williams RO. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum. 2008;58(4):1038-43.
36. Ding Y, Yang H, Xiang W, He X, Liao W, Yi Z. CD200R1 agonist attenuates LPS-induced inflammatory response in human renal proximal tubular epithelial cells by regulating TLR4-MyD88-TAK1-mediated NF-kappa B and MAPK pathway. Biochem Biophys Res Comm. 2015;460(2):287-94.
37. Hylden JLK, Wilcox GL. Intrathecal morphine in mice-a new technique. Eur J Pharmacol. 1980;67(2-3):313-6.
38. Zamboni L, Demartin C. Buffered picric acid-formaldehyde-a new rapid fixative for electron microscopy. J Cell Biol. 1967;35(2P2):A148.
39. Brazda V, Muller P, Brozkova K, Vojtesek B. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Biochem Biophys Res Comm. 2006;351(2):499-506.
40. Ren Y, Yang B, Yin Y, Leng X, Jiang Y, Zhang L, et al. Aberrant CD200/CD200R1 expression and its potential role in Th17 cell differentiation, chemotaxis and osteoclastogenesis in rheumatoid arthritis. Rheumatology. 2015;54(4):712-21.
41. Austin PJ, Moalem-Taylor G. Animal models of neuropathic pain due to nerve injury. Neuromethods. 2013;78:239-60.
42. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33(1):87-107.
43. Maves TJ, Pechman PS, Gebhart GF, Meller ST. Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain. 1993;54(1):57-69.
44. Pineau I, Lacroix S. Endogenous signals initiating inflammation in the injured nervous system. Glia. 2009;57(4):351-61.
45. Guo W, Wang H, Watanabe M, Shimizu K, Zou SP, LaGraize SC, et al. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci. 2007;27(22):6006-18.
46. Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A. 2007;104(25):10655-60.
47. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003;306(2):624-30.
48. Gorczynski RM, Cattral MS, Chen ZG, Hu JA, Lei J, Min WP, et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo-and xenograft survival. J Immunol. 1999;163(3):1654-60.
49. Wang W, Mei XP, Huang J, Wei YY, Wang YY, Wu SX, et al. Crosstalk between spinal astrocytes and neurons in nerve injury-induced neuropathic pain. Plos One. 2009;4(9):10.
50. Padi SSV, Kulkarni SK. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol. 2008;601(1-3):79-87.
51. Morioka N, Zhang FF, Nakamura Y, Kitamura T, Hisaoka-Nakashima K, Nakata Y. Tumor necrosis factor-mediated downregulation of spinal astrocytic connexin43 leads to increased glutamatergic neurotransmission and neuropathic pain in mice. Brain Beh Immun. 2015;49:293-310.
52. Beggs S, Salter MW. Stereological and somatotopic analysis of the spinal microglial response to peripheral nerve injury. Brain Beh Immun. 2007;21(5):624-33.
53. Blackbeard J, O'Dea KP, Wallace VCJ, Segerdahl A, Pheby T, Takata M, et al. Quantification of the rat spinal microglial response to peripheral nerve injury as revealed by immunohistochemical image analysis and flow cytometry. J Neurosci Meth. 2007;164(2):207-17.
54. Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain. 2013;154:S10-28.
55. Mika J, Osikowicz M, Rojewska E, Korostynski M, Wawrzczak-Bargiela A, Przewlocki R, et al. Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur J Pharmacol. 2009;623(1-3):65-72.
56. Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KHG, Lynch MA. CD200 ligand-receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci. 2007;27(31):8309-13.
57. Cregg JM, DePaul MA, Filous AR, Lang BT, Tran A, Silver J. Functional regeneration beyond the glial scar. Exp Neurol. 2014;253:197-207.
58. Nolte C, Matyash M, Pivneva T, Schipke CG, Ohlemeyer C, Hanisch UK, et al. GFAP promoter-controlled EGFP-expressing transgenic mice: a tool to visualize astrocytes and astrogliosis in living brain tissue. Glia. 2001;33(1):72-86.
59. Lan L, Yuan H, Duan L, Cao R, Gao B, Shen J, et al. Blocking the glial function suppresses subcutaneous formalin-induced nociceptive behavior in the rat. Neurosci Res. 2007;57(1):112-9.
60. Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E, Przewlocka B. Importance of glial activation in neuropathic pain. Eur J Pharmacol. 2013; 716(1-3):106-19.
61. Feng XM, Zhang FJ, Dong R, Li WY, Liu J, Zhao X, et al. Intrathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia. Eur J Pharmacol. 2009;614(1-3):38-43.
62. Kersten C, Cameron MG, Laird B, Mjaland S. Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain. Br J Anaesth. 2015;115(5):761-7.
63. Xin Q, Cheng B, Pan Y, Liu H, Yang C, Chen J, et al. Neuroprotective effects of apelin-13 on experimental ischemic stroke through suppression of inflammation. Peptides. 2015;63:55-62.
64. Zhang S, Wang XJ, Tian LP, Pan J, Lu GQ, Zhang YJ, et al. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J Neuroinflamm. 2011;8:154.
65. Narita M, Yoshida T, Nakajima M, Narita M, Miyatake M, Takagi T, et al. Direct evidence for spinal cord microglia in the development of a neuropathic pain-like state in mice. J Neurochem. 2006;97(5):1337-48.
66. Kleinschnitz C, Brinkhoff J, Sommer C, Stoll G. Contralateral cytokine gene induction after peripheral nerve lesions: dependence on the mode of injury and NMDA receptor signaling. Mol Brain Res. 2005;136(1-2):23-8.
67. Latremoliere A, Mauborgne A, Masson J, Bourgoin S, Kayser V, Hamon M, et al. Differential implication of proinflammatory cytokine interleukin-6 in the development of cephalic versus extracephalic neuropathic pain in rats. J Neurosci. 2008;28(34):8489-501.
68. Uceyler N, Tscharke A, Sommer C. Early cytokine gene expression in mouse CNS after peripheral nerve lesion. Neurosci Lett. 2008;436(2):259-64.
69. Sacerdote P, Franchi S, Moretti S, Castelli M, Procacci P, Magnaghi V, et al. Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain. J Neuroimmun Pharmacol. 2013;8(1):202-11.
70. Wilkerson JL, Gentry KR, Dengler EC, Wallace JA, Kerwin AA, Armijo LM, et al. Intrathecal cannabilactone CB2R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain. 2012;153(5):1091-106.
71. Milligan ED, Sloane EM, Langer SJ, Cruz PE, Chacur M, Spataro L, et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005;1:9.
72. Uceyler N, Topuzoglu T, Schiesser P, Hahnenkamp S, Sommer C. IL-4 deficiency is associated with mechanical hypersensitivity in mice. Plos One. 2011;6(12):e28205.
73. Lyons A, Downer EJ, Costello DA, Murphy N, Lynch MA. Dok2 mediates the CD200Fc attenuation of A beta-induced changes in glia. J Neuroinflamm. 2012;9:107.
74. Cox FF, Berezin V, Bock E, Lynch MA. The neural cell adhesion moleculederived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a cd200-dependent manner. Neurosci. 2013;235:141-8.